Clinically significant for its involvement in inflammatory diseases, MK2 is a promising therapeutic target in conditions such as rheumatoid arthritis and certain cardiovascular diseases, where excessive inflammation is a hallmark.48,49 As a result, MK2 inhibitors are being actively explored for their potential to modulate inflammatory pathways and bring therapeutic benefits without broadly suppressing the immune system. The gene discussed is MAPKAPK2; the disease is rheumatoid arthritis.